ARCHIMED, a global private equity firm specializing in healthcare, has acquired a majority stake in Cellese, a developer of innovative dermo-cosmetics sold under the AnteAGE brand. Located in Irvine, California, Cellese focuses on harnessing the body’s natural regenerative properties through growth factors and exosomes. The acquisition aims to leverage ARCHIMED’s strategic resources to accelerate Cellese’s edge in regenerative skincare. Cellese’s CEO, Ian Sanderson, stated that several parties were eager to invest, but ARCHIMED’s understanding of the market and commitment to supporting their vision were decisive factors. Cellese’s revenues have grown 70% annually since 2020, and the company distributes its products globally. This acquisition marks the sixth investment by ARCHIMED’s MED III fund, which has targeted small-cap healthcare companies.
Private Equity, Healthcare, Consumer Goods,United States, Global
https://archimed.group/news/archimed-buys-cellese-a-pioneering-developer-of-growth-factors-and-exosome-based-skincare-products/